Keith Duplantis, MD
Interventional Pain Medicine · Houma, LANPI 1932379872
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,326 of the $6,096 with a category attached, or 87.4%. It is spread thinly across 36 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,748 and has fallen 51.2% since, to $854 in 2025.
Across 278 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Stryker$1K
- AbbVie$636
- Collegium Pharmaceutical, Inc.$403
- Amgen$301
- Pfizer$286
- plus $2K from 30 others
What the payments were for
- Travel & lodging$77013%
- Food & beverage$5,32687%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 69 | $1,309 |
| Stryker | 8 | $1,118 |
| AbbVie(2 entities) | 44 | $636 |
| Collegium Pharmaceutical, Inc. | 21 | $403 |
| Amgen(2 entities) | 17 | $301 |
| Pfizer | 15 | $286 |
| Biotronik NRO, Inc. | 6 | $255 |
| AstraZeneca | 2 | $182 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $167 |
| Medtronic(2 entities) | 14 | $134 |
| Redhill Biopharma Inc. | 7 | $121 |
| Avanos Medical | 1 | $112 |
| Nevro Corp. | 6 | $102 |
| Arbor Pharmaceuticals, Inc. | 8 | $97 |
| Teva Pharmaceuticals USA, Inc. | 7 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $88 |
| Fidia Pharma USA Inc. | 4 | $82 |
| Stimwave Technologies Incorporated | 1 | $78 |
| Sentynl Therapeutics, Inc. | 6 | $76 |
| Biodelivery Sciences International, Inc. | 2 | $61 |
| Novartis | 3 | $55 |
| Eisai Inc. | 3 | $48 |
| Zyla Life Sciences, Inc. | 2 | $46 |
| Azurity Pharmaceuticals, Inc. | 2 | $36 |
| Bioventus LLC | 1 | $28 |
| Lilly USA, LLC | 2 | $28 |
| Shionogi Inc | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Almatica Pharma LLC | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Nalu Medical, Inc. | 1 | $14 |
| Virtus Pharmaceuticals LLC | 1 | $14 |
| Hydrocision, Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
| Si-bone, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,096 in reported general payments places this provider in the 60th percentile of 57 interventional pain medicine providers in Louisiana.
See all interventional pain medicine providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 72 | $36,239 |
| MovantikNaloxegol Oxalate | 52 | $35,767 |
| UbrelvyUbrogepant | 30 | $35,614 |
| BotoxOnabotulinumtoxina | 26 | $34,171 |
| QuliptaAtogepant | 27 | $31,856 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,313 | $31,349 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,232 | $31,283 |
| Chlorzoxazone | 491 | $31,065 |
| OxycontinOxycodone Hcl | 51 | $19,833 |
| Hysingla ErHydrocodone Bitartrate | 31 | $14,746 |
| BelbucaBuprenorphine Hcl | 18 | $14,423 |
| Amitriptyline Hcl | 699 | $9,353 |
| Gabapentin | 385 | $8,309 |
| Pregabalin | 482 | $7,851 |
| Tramadol Hcl ErTramadol Hcl | 38 | $6,520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Botox, Qulipta | $636 | $101,64183 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $403 | $50,66290 claims |
| Redhill Biopharma Inc.Movantik | $121 | $35,76752 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 57 interventional pain medicine providers in Louisiana.
Other interventional pain medicine in Houma
- Maged GuirguisNew Orleans$565K
- Suneil JollyKenner$107K
- John CefaluShreveport$71K
- Steve LeeSlidell$57K
- William WhyteShreveport$39K
- Paul HubbellMetairie$33K
- Ken EhrhardtHammond$22K
- Thomas BerryLacombe$21K
- Randall BrewerShreveport$19K
- Corey Ann ConnCovinton$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.